Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Randall F. Holcombe
A Phase II Trial of Gemcitabine and Capecitabine in Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma: Southwest Oncology Group Study S0202
Cancer Chemotherapy and Pharmacology
Cancer Research
Toxicology
Oncology
Pharmacology
Standardized Cancer Incidence Disparities in Upper Manhattan New York City Neighborhoods
European Journal of Cancer Prevention
Oncology
Epidemiology
Cancer Research
Public Health
Environmental
Occupational Health
Related publications
SWOG 0514: A Phase II Study of Sorafenib in Patients With Unresectable or Metastatic Gallbladder Carcinoma and Cholangiocarcinoma
Investigational New Drugs
Oncology
Pharmacology
A Phase II Trial of Fixed-Dose Rate Gemcitabine Plus Capecitabine in Metastatic/Advanced Biliary Tract Cancer Patients
Oncology
Medicine
Cancer Research
Oncology
Front-Line Treatment With Gemcitabine, Paclitaxel, and Doxorubicin for Patients With Unresectable or Metastatic Urothelial Cancer and Poor Renal Function: Final Results From a Phase II Study
Urology
Urology
Phase II Study of Carboplatin, Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer
The Internet Journal of Oncology
Phase II Trial of Imatinib in Metastatic or Unresectable Gastrointestinal Stromal Tumors,NEMROCK Experience.
Research in Oncology
Phase II Study of Aflibercept (VEGF-Trap) in Patients With Recurrent or Metastatic Urothelial Cancer, a California Cancer Consortium Trial
Urology
Urology
A Phase II Study of Axalimogene Filolisbac for Patients With Previously Treated, Unresectable, Persistent/Recurrent Loco-Regional or Metastatic Anal Cancer
Oncotarget
Oncology
A Phase II Study of NK012, a Polymeric Micelle Formulation of SN-38, in Unresectable, Metastatic or Recurrent Colorectal Cancer Patients
Cancer Chemotherapy and Pharmacology
Cancer Research
Toxicology
Oncology
Pharmacology
Phase II Trial of Gemcitabine and Tanespimycin (17AAG) in Metastatic Pancreatic Cancer: A Mayo Clinic Phase II Consortium Study
Investigational New Drugs
Oncology
Pharmacology
